Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 5/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.37 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.37 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | REN | P00797 | 4/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | BCR | P11274 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5873073 | 0.92 | PIM1 (0.40) | HCRTR1HCRTR2PIM1ABL1BCR | |
| SCHEMBL5873067 | 0.92 | MKNK1 (0.43) | MKNK1MKNK2PIM1PIM3PIM2 | |
| SCHEMBL5872961 | 0.90 | NAMPT (0.38) | HCRTR1HCRTR2PIM1KDM5AABL1 | |
| SCHEMBL5872872 | 0.88 | MKNK1 (0.45) | MKNK1MKNK2PIM1PIM3PIM2 | |
| SCHEMBL5873068 | 0.87 | ALDH1A1 (0.42) | — | |
| SCHEMBL5872987 | 0.87 | MKNK1 (0.44) | MKNK1MKNK2HCRTR1HCRTR2MAPK14 | |
| SCHEMBL5872927 | 0.86 | ALDH1A1 (0.41) | HCRTR1HCRTR2NAMPT | |
| SCHEMBL5873098 | 0.86 | KDM5A (0.39) | HCRTR1HCRTR2PIM1KDM5A | |
| SCHEMBL5872940 | 0.85 | MKNK1 (0.42) | MKNK1MKNK2PIM1PIM3PIM2 | |
| SCHEMBL5872979 | 0.85 | PIM1 (0.40) | PIM1PIM3PIM2LRRK2NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984652-B2 | Gyrase inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-10 | — | — | US | disclosed |
| US-20050250823-A1 | Gyrase inhibitors | YAGER KRAIG | 2005-11-10 | — | — | US | disclosed |
| US-20050054697-A1 | Gyrase inhibitors | PFIZER INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054697-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | MKNK1 2151/4885MKNK2 2127/4885HCRTR1 4881/4885 |
| US-20050250823-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | MKNK1 2151/4885MKNK2 2127/4885HCRTR1 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.